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INTRODUCTION
Non-Hodgkin’s lymphomas (NHL) as other lym-
phoproliferative disorders (LPD) are accompanied with 
a high frequency of autoimmune processes among which 
the autoimmune cytopenias prevail [1, 2]. In particu-
lar, the autoimmune hemolytic anemia (AIHA), mostly 
due to warm antibodies (positive direct Coombs’ test), 
accounts for 2.6–3.0% of all cases of NHL [3, 4]. It is 
frequently combined with an immune thrombocytope-
nia (ITP) and immune leukopenia, the immune char-
acteristics of which are more difficult to confirm, since, 
thrombocytopenia and leukopenia may be a manifes-
tation of hypersplenism in massive splenomegaly [5]. 
The pathogenesis of autoimmune processes in lymphoid 
proliferations remains a matter of considerable dispute 
and controversy, especially as a high frequency of LPD 
is also observed in AIHA [6]. It is believed that increased 
tendency to autoimmune antibodies formation in LPD 
is caused by rearrangements of the immunoglobulin V-
region genes or T-cell receptor in the malignant B-/T-
cells. It triggers the generation of autoreactive lympho-
cyte clones. Failure to eliminate these clones or the break-
down in the mechanisms that prevent their expansion 
may lead to the occurrence of autoimmune processes [4].
NHL with autoimmune cytopenias requires speci fic 
treatment approach that is caused by a whole range of 
conditions. It has been proved that the presence of AIHA 
in patients with NHL is an adverse prognostic sign [4]. 
Autoimmune process of such patients shows a poor re-
sponse to corticosteroids and intravenous immunoglo-
bulin, and slightly better response to cytostatic therapy 
of lymphoma [1, 3]. Finally, the massive splenomegaly 
with all possible consequences (abdominal discomfort, 
regional portal hypertension (RPH), hypersplenism) is 
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often observed in these NHL [5, 7, 8]. In such cases, the 
need for splenectomy arises having positive outcomes as 
well as some risk for a patient [7, 9].
The aim of this study was to specify the indications 
for surgical equipment and consequences of splenecto-
my in NHL associated with AIHA or Evans — Fisher 
syndrome (EFS) as based on twenty years’ experience 
of performance of the surgery in our clinic.
MATERIALS AND METHODS
During the period of 1986–2015 at the Department of 
Surgery and Clinical Transfusion Medicine of the State 
Institution «Institute of Blood Pathology and Transfu-
sion Medicine of National Academy of Medical Scien-
ces of Ukraine» (Lviv) and at the premises of the Depart-
ment of Surgery of Lviv City Communal Clinical Hos-
pital No. 5 among 107 splenectomies in patients with 
NHL, 10 splenectomies were performed in patients with 
NHL and AIHA (group 1) and 18 splenectomies were 
performed in patients with NHL associated with AIHA 
and ITP — EFS (group 2).
The diagnostics of NHL and its variant was per-
formed as based on the results of the clinical and instru-
mental examinations (Table 1), cytological examination 
of periphe ral blood, bone marrow, aspirates and imprints 
of the affected organs, histological examination of biop-
sy specimens of the removed lymph nodes and/or spleen, 
immunophenotypic features of malignant cells of the in-
vestigated tissues in accordance with current classifica-
tions (WF, REAL with further specification pursuant to 
WHO classification) [10] (Table 2). The extending (stage) 
of the disease was estimated on grounds of clinical, X-ray, 
ultrasonographic examinations and computed tomogra-
phy according to Ann Arbor staging system [11]. 15 pa-
tients were diagnosed with III-E or III-Es stage disease, 
and 13 patients were diagnosed with IV stage disease.
Splenectomy was performed under intubation anesthe-
sia via the upper middle laparotomy. In patients with mas-
sive splenomegaly (spleen weight > 3 kg), marked perisple-
nitis and vascular anastomoses among organs resulting from 
RPH the laparotomy incision was exten ded towards pubic 
articulation or supplemented by a lateral incision on the left 
2 cm above the umbilicus. The classical technique for sple-
nectomy was applied. The enlarged spleen removal was start-
ed with mobilization of the inferior pole that technically al-
lowed for a control of the splenic pedicle vessels, gradual 
visualization of splenic ligaments and junctions, and its dis-
section while systema tically attaining hemostasis by virtue 
of vascular ligation or electrocoagulation. After releasing the 
spleen from liga ments and junctions and its exterio rization, 
the vascular pedicle and other vessels were ligated. Since 2002 
all patients were immunized with vaccine Pneumo-24 and 
recently with Prevenar vaccine before splenectomy in order 
to prevent post-splenectomy infection.
The results of splenectomy were assessed in the imme-
diate post-splenectomy period (on the fourteenth- sixteenth 
day) pursuant to criteria described in the referen ces [12] and 
during follow-up control. The follow-up period after the 
surgery ranged between 3 and 201 months (median time 
68 months) for group 1, and between 1 and 290 months (me-
dian time 195.5 months) for group 2.
The results were analyzed by means of descriptive statis-
tical methods. The event-free survival (event — recurrence of 
immune cytopenia or when a patient died of lymphoma) and 
overall patients’ survival were determined by the Kaplan — 
Meier method and described as a median survival (lower-
Table 1
Clinical and hematologic characteristics and results of splenectomy 
in patients with NHL associated with immune cytopenias
Criteria NHL + AIHA NHL + AIHA + ITP
Number of patients 10 18
Sex: male/female 6/4 12/6
Age > 60 years 2 5
Disease duration before splenectomy 
(months) 1–48 2–132
General condition according to ECOG ≥ 2 1 2
Clinical signs
Peripheral lymph nodes 4 5
Mediastinal lymph nodes 2 2
Intra-abdominal lymph nodes 10 14
Splenomegaly 10 18
Hepatomegaly 5 13
Bone marrow involvement ≥ 30%  
of lymphoid cells
3 9
Stage of disease:
ІІІ
ІV
3
7
12
6
Indices of peripheral blood
Anemia < 100 g/l 8 10
Thrombocytopenia < 100•109/l − 18
Leukocytosis > 10•109/l 3 7
Lymphocytosis 5–10•109/l − 2
Lymphocytosis ≥ 10•109/l 2 6
Leukopenia ≤ 3.5•109/l 4 8
Reticulocytes > 20‰ 10 13
Erythrocyte sedimentation rate > 20 mm/h 7 14
М-gradient 1 2
Therapy before splenectomy 6 9
Intraoperative indices
Massive splenomegaly  
(weight > 1500 g) 10 12
Perisplenitis 1 6
Regional portal hypertension 6 12
Ascite 3 3
Bleeding during surgery 3 10
Blood loss > 500 ml 3 6
Response to splenectomy
Remission > 12 months
Remission 2–12 months
Absence of remission (progression)
4
6
−
5
11
2
No need for treatment after splenectomy
Received treatment after splenectomy
9
1
12
6
Table 2
Morphological variants of NHL with immune cytopenias
Types of NHLs
NHL + AIHA
(number 
of patients)
NHL + AIHA + 
ITP (number 
of patients)
Splenic lymphoma with villous lympho-
cytes (SLVL) − 5
Splenic marginal zone lymphoma (SMZL) 2 3
Nodal marginal zone lymphoma (NMZL) 1 –
Follicular lymphoma − 1
Mantle cell lymphoma (MCL) – 3
Diffuse large B-cell lymphoma (DLBCL) 6 5
В-cell NHL, unclassified 1 –
T-cell NHL, unclassified – 1
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upper quartiles) and 3-year and 5-year survival. The surviv-
al curves were compared using the log-rank test.
RESULTS AND DISCUSSION
Splenectomy was performed in 10 patients with NHL 
associated with warm-antibody AIHA. Among them there 
were 6 men and 4 women 25–68 years old (median age — 
51.5 years). All patients, except for one of them, were in sat-
isfactory clinical condition complaining of general weak-
ness, easy fatigability and weight loss (grade 1–2 according 
to ECOG scale). The disease duration before splenecto-
my ranged from 1 to 48 months. Enlargement of peripheral 
lymph nodes occurred in 4 patients, mediastinal — in 2 pa-
tients, and enlargement of intra-abdominal lymph nodes was 
observed in all patients. Splenomegaly was found in all sub-
jects, thereby, in 4 patients the spleen occupied all the left 
side of the abdomen, in 2 patients — it occupied the whole 
abdomen and its inferior pole descended into the small pel-
vis. Hepatomegaly (the liver protruded below the edge of the 
costal margin to 1–6 cm) was observed in 5 patients of the 
group. Bone marrow involvement (> 30% of lymphoid cells) 
was found in 3 patients with peri pheral blood lymphocyto-
sis > 10.0•109/l in 2 cases. M-gradient (see Table 1) appears 
on proteinogram of 1 patient with NMZL. Classification of 
patients according to NHL variants is presented in Table 2.
All patients showed signs of profound hemolysis: icter-
ic skin and mucosa, anemia (8 patients showed hemoglo-
bin level of 60–96 g/l), reticulocytosis 20–128‰ accom-
panied by increased total bilirubin due to indirect fraction, 
and in particular cases, followed by increased transaminase 
level, positive direct Coombs’ test and warm agglutinins. 
Leukopenia (1.0–3.5•109/l) occurred in 4 patients. In one 
patient, hemolysis was the first sign of disease, while in 
other patients it occurred after NHL manifestations. Ab-
dominal manifestations (discomfort and pain in the left 
hypochondriac region) were noticed in 5 patients. RPH 
was sonographically diagnosed in 5 patients based on in-
creased diameter of the splenic and portal veins.
Six patients administered corticosteroids, under-
went chemotherapy, erythrocyte transfusions before sur-
gery, however, that has not resulted in hemolysis cessa-
tion. Thus, the indications for splenectomy in the pa-
tients with NHL associated with AIHA were as follows: 
profound hemolysis which was refractory to drug thera-
py, leukopenia as a possible manifestation of hypersple-
nism, massive splenomegaly with abdominal symptoms, 
and presence of RPH.
In 3 patients splenectomy was followed by blood loss 
of more than 500 ml secondary to enlarged spleen, peri-
splenitis, excessive bleeding and RPH. In other cases 
(7 patients), the surgery was performed without compli-
cations with blood loss of less than 500 ml. The ascitic 
fluid was found in 3 patients. The weight of the removed 
spleens ranged from 1.5 to 10.0 kg. Abdominal lymph-
adenopathy was confirmed in all patients of group 1; en-
larged lymph nodes only at splenic hilum were observed 
in 3 patients, in other 7 patients the lymph node packages 
were found along the lesser and greater curvatures of the 
stomach, in the hepatoduodenal ligament, at the splenic 
and renal hilums, along the upper edge of the pancreas, 
and enlarged mesenteric lymph nodes were also found. 
One patient had two accessory spleens removed, and an-
other patient simultaneously underwent cholecystecto-
my for chronic calculous cholecystitis.
The histologic and immunohistochemical exami-
nations of the removed spleens (including two accesso-
ry spleens) and abdominal lymph nodes confirmed the 
initial diagnosis of NHL variant in 5 patients. In another 
5 patients who had no affected peripheral lymph nodes 
and/or leukemization available for morphological exami-
nation the variant of lymphoma was determined or speci-
fied that substantiates the diagnostic significance of sple-
nectomy for these patients.
Complications occurred in 2 (20%) patients in the 
postoperative period. One patient developed a bilater-
al pneumonia that was resolved after proper antibacte-
rial therapy. Another patient developed a lower extrem-
ity superficial thrombophlebitis in varicose veins sec-
ondary to post-splenectomy hyperthrombocytosis; the 
thrombectomy was performed (Table 3). The immediate 
result of splenectomy in all of the patients (100%) with 
NHL associated with AIHA was good: hemolysis ceased, 
hemoglobin level increased, in patients with leukopenia 
the leukocytes stabilized, bilirubin level reduced to the 
normal value, M-gradient disappeared, and no mani-
festations of abdominal discomfort were observed. Only 
one (10%) patient of group 1 required cytostatic thera-
py within the 1-year period after surgery.
Table 3
Complications after splenectomy in patients with NHL  
with immune cytopenias
Type of complications NHL + AIHA NHL + AIHA + ITP
Pneumonia 1 1
Acute postoperative hemorrhage − 1
Acute thrombophlebitis of the lower  
extremity superficial veins 1 −
Postoperative pancreatitis − 2
Acute adrenal insufficiency − 1
While analyzing the long-term outcomes of splen ectomy 
in patients with NHL associated with AIHA it has been de-
fined that the median event-free survival was 29 months 
(12–49 months) (Fig. 1), and the median overall surviv-
al — 31 month (18.1–52.2 months) with the 3-year surviv-
al rate of 45% and 5-year survival rate of 22% (Fig. 2). The 
patient with NMZL had the shor test survival time after the 
surgery (3 months), and the best effect has been achieved in 
patient with mature B-cell NHL (low-grade malignancy ac-
cording to WF). In this patient, NHL and massive spleno-
megaly has been associated with warm type AIHA (hemo-
globin level — 50 g/l) and leukopenia (1.4•109/l). Numer-
ous blood transfusions, chemotherapy and corticosteroids 
therapy had no effect. The patient underwent splenectomy. 
The removed spleen weight constituted 10 kg. Splenecto-
my resulted in termination of hemolysis, leukocytes stabili-
zation, and elimination of abdominal discomfort caused by 
giant spleen. The patient has been living for 201 months af-
ter the splenectomy having achieved complete clinical re-
mission, without any additional treatment.
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Fig. 1. The Kaplan — Meier curves of overall survival in pa-
tients with NHL, associated with АІHА, and NHL, associa-
ted with АІHА and ІТP
Fig. 2. The Kaplan — Meier curves of event-free survival in pa-
tients with NHL, associated with АІHА, and NHL, associa-
ted with АІHА and ІТP
One patient with SMZL (who underwent surgery when 
there was no possibility to perform prophylactic vacci-
nation) died 9 months after splenectomy due to untreat-
ed post-splenectomy infection (overwhelming postsple-
nectomy infection syndrome) that manifested as a sep-
tic shock. Antibiotic therapy and resuscitation at Intense 
Care Unit proved ineffective, and the patient died. In pa-
tients with DLBCL (n=6), despite good short-term results 
of splenectomy, the median overall survival was short — 
26 months, wherein, five of them died of lymphoma pro-
gression, and one of them — died of myocardial infarc-
tion 64 months after the surgery.
In group 2, there were 18 patients with NHL associa-
ted with AIHA and ITP (EFS), 12 of them were men (25–
65 years old) and 6 of them were women (56–69 years 
old), the median age — 53.5 months. General condition of 
16 patients corresponded to grade 1–2 according to ECOG 
scale, and condition severity of two patients corresponded 
to grade 3. The disease duration before surgery ranged from 
1 month to 11 years. Five patients were diagnosed with en-
largement of peripheral lymph nodes. All of the patients suf-
fered from a pronounced splenome galy: in 10 patients the 
spleen occupied all the left side of the abdomen, in 4 pa-
tients it protruded beyond the median line and its inferi-
or pole descended into the small pelvis. Hepatomegaly was 
observed in 13 cases. During instrumental examination of 
the chest and abdominal cavity all patients were diagnosed 
with splenomegaly, abdominal (14 patients) and mediasti-
nal lymphadenopathy (2 patients). Bone marrow involve-
ment was found in 9 patients, lymphoid cells count in the 
bone marrow exceeded 30%. M-gradient in blood serum 
was revealed in two subjects with lymphoma (see Table 1).
All patients showed signs of profound hemolysis, had 
positive direct Coombs’ test and warm agglutinins. Reduced 
hemoglobin level of less than 100 g/l was observed in 10 pa-
tients, the number of reticulocytes varied from 22 to 138‰. 
Bilirubin concentration in blood increased due to indirect 
fraction. At the same time these patients were diagnosed 
with thrombocytopenia: number of thrombocytes ranged 
from minimum values to 92.0•109/l. However, moderate 
hemorrhages (skin petechiae, mucosal and abdominal he-
morrhages) occurred only in one patient with DLBCL when 
thrombocytes number was less than 30•109/l. The number 
of leukocytes remained within normal range only in 3 pa-
tients, 8 patients were diagnosed with leukopenia, and an-
other 7 were diagnosed with leukocytosis. Absolute lympho-
cytosis 5–10•109/l was noticed in 2 patients, and more than 
10•109/l — was observed in 6 patients. In 5 patients with 
EFS, the atypical morphology of peripheral blood lympho-
cytes which corresponded to villous lymphocytes morpho-
logy was determined that constituted a ground for diagnosing 
SLVL [13, 14]. Marked manifestations of abdominal discom-
fort were noticed in 12 patients. 15 patients developed signs 
of RPH: increase in diameter of splenic vein (15 patients), in-
crease in diameter of portal vein (9 patients), grade 1 esopha-
geal varices determined by fibrogastroduodenoscopy (3 pa-
tients). Classification of patients according to NHL variants 
is presented in Table 2.
Nine patients of group 2 received treatment (chemo-
therapy, corticosteroids) before the surgery without possi-
ble effect on immune cytopenia. The indications for sple-
nectomy in patients with NHL associated with AIHA and 
ITP were as follows: AIHA, thrombocytopenia, hemor-
rhagic syndrome, previous treatment failure, splenomegaly 
with abdominal manifestations and hypersplenism, RPH.
The spleen removal in patients of group 2 was techni-
cally difficult. In 6 patients the surgery was associated with 
marked perisplenitis in the form of adhesions of the spleen 
to the diaphragm, abdominal wall, colon and left kidney. 
9 patients developed the increased bleeding, apparent-
ly secondary to thrombocytopenia, due to which the dif-
ferent hemostatic methods were applied: pharmacologi-
cal method, electrocoagulation, tamping with hemostatic 
sponge, and in particular cases — with gauze pads. In one 
patient the upper middle laparotomy incision had to be 
supplemented by oblique incision in the left hypochon-
driac region due to marked perisplenitis, massive spleno-
megaly and excessive bleeding.
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The weight of the removed spleens ranged from 1.5 to 
6.0 kg, where in 12 cases the spleen was particularly large-
sized (26–45 cm long). In one case the accessory spleens 
located at the hilum of the main spleen were detected and 
removed. The surgical blood loss constituted 200–1000 ml. 
The enlarged abdominal lymph nodes (14 patients) were 
detected mostly at the splenic hilum, along the greater cur-
vature of the stomach, along the upper edge of the pancre-
as, less frequently — in the hepatoduo denal ligament, as 
well as enlarged paraaortic and mesenteric lymph nodes. 
In 10 patients the RPH was manifested by splenic, abdom-
inal, diaphragmatic and omental varices; and the ascitic 
fluid was found in 3 patients.
The morphological and immunological examinations 
of the spleen and abdominal lymph nodes confirmed the 
diagnosis of NHL variant in 11 patients, enabled to de-
termine or specify the lymphoma variant in 6 patients, 
and in one case it constituted a ground for changing the 
initial diagnosis of myelofibrosis for T-cell lymphoma 
(high-grade according to WF). Thus, the splenectomy 
was diagnostically significant for 7 patients.
The short-term results of splenectomy in 16 (89%) 
patients of group 2 were classified as good: hemoly-
sis ceased, hemoglobin level has stabilized, number of 
thrombocytes increased or stabilized, in patients with leu-
kopenia the leukocytes stabilized, in particular patients 
with leukocytosis the number of leukocytes reduced, and 
the abdominal discomfort syndrome was eliminated. The 
M-gradient disappeared in one patient with a MCL.
The splenectomy proved ineffective in two (11%) pa-
tients of group 2. In one patient with DLBCL associated with 
AIHA and ITP with severe hemorrhagic syndrome, leuko-
penia, massive (30×15 cm) spleen adjacent to the neighbor-
ing organs and abdominal wall, collateral varices in the ab-
dominal cavity, the splenectomy was accompanied by great 
technical difficulties and excessive bleeding (blood loss — 
1000 ml). The surgery has not resul ted in hemolysis termi-
nation and increasing thrombocyte count, the patient died 
one month after splenectomy due to hemorrhagic syndrome. 
Another patient was admitted with a provisional diagno-
sis of myelofibrosis, splenome galy, AIHA (hemoglobin — 
51 g/l, positive Coombs’ test), ITP (thrombocytes count — 
34.0•109/l), and leukopenia (3.9•109/l). Due to splenomeg-
aly, concomitant pancytopenia refractory to corticosteroids 
and for diagnosis confirmation the patient was assigned to 
undergo splenectomy. The surgery was accompanied by great 
technical difficulties, bleeding (blood loss — approximate-
ly 1000 ml) as a consequence of perisplenitis, thrombocy-
topenia and RPH. A high-grade (according to WF) malig-
nant T-cell lymphoma was found in the removed spleen by 
means of morphological examination. On the twelfth day 
after splenectomy the peripheral blood indices improved 
(hemoglobin — 98 g/l, leukocytes — 27.0•109/l, thrombo-
cytes — 589.0•109/l). However, the patient’s condition re-
mained unstable and he died one month after the surgery 
due to rapid progression of the lymphoma.
Complications after splenectomy (Table 3) occurred in 3 
(17%) patients of group 2. The patient with SMZL deve loped 
pneumonia and postoperative pancreatitis after splenecto-
my. Both complications were successfully cured. The patient 
with SMZL and M-gradient in spite of pre- and periopera-
tive bleeding prevention and unassociated with surgery de-
veloped intra-abdominal bleeding 2 hours after splenecto-
my, which was successfully suppressed with great difficul-
ties without relaparotomy after consecutive administration 
of haemostatic agents, eptacog alfa, human prothrombin 
complex, fresh frozen plasma transfusion and finally, local 
administration of aprotinin. On the fifth day after the sur-
gery the same patient developed postoperative pancreatitis 
that was timely diagnosed and treated. The acute adrenal in-
sufficiency which was manifested by a sudden drop in blood 
pressure occurred in patient with MCL on the second day 
after the surgery. The patient’s condition has stabilized af-
ter high corticosteroids dose administration. Six (33%) pa-
tients of group 2 underwent cytostatic therapy in the first 
year after the surgery.
While analyzing the long-term outcomes of splen-
ectomy in patients with NHL associated with AIHA and ITP 
(Fig. 1, 2) it has been defined that the median event-free sur-
vival after the surgery was 22 months (5–52 months), and 
the median overall survival — 50 months (12–97 months) 
with the 3-year survival rate of 62% and 5-year survival rate of 
31%. Depending on lymphoma’s category the overall median 
survival time after splenectomy in patients of this group with 
SLVL constituted 39.8 months, with MCL — 159.7 months, 
with DLBCL — 21.4 months. The median event-free survi-
val in patients with SLVL constituted 10.6 months, with 
MCL — 6.3 months and with DLBCL — 21.4 months. 
One patient with follicular lymphoma has lived 6 months 
after splenectomy and died due to the disease progression; 
another patient with SMZL has lived 143 months after the 
surgery without chemotherapeutic agents’ administration.
Statistical comparison of overall and event-free sur-
vival after splenectomy showed no significant difference 
between the 2 groups (long-rank test for overall survi-
val p = 0.97607, for event-free survival — p = 0.21350).
Thus, similar to other researchers [5, 8, 12, 15–19], we 
determined that splenectomy remains an effective and rel-
atively safe method for treating NHL associated with im-
mune cytopenias. Indications for splenectomy in patients 
of the represented groups were both diagnostic and thera-
peutic. Similar indications are discussed in the references [8, 
16, 18, 20]. Most of patients showed more than one indica-
tion for the surgery that is mentioned in the references [16].
The splenectomy was diagnostically significant for 12 
(43%) patients of both groups who suffered from isolat-
ed splenomegaly without involvement of accessible lymph 
nodes and bone marrow that is closely related to the issue of 
splenic lymphomas [20]. As a result of histological and im-
munophenotypic analysis of the affected splenic tissue, the 
diagnosis of NHL variant was determined or specified in 
11 patients, and T-cell lymphoma with the initial diagnosis 
of myelofibrosis was found in one case.
An alternative to splenectomy in such patients (while 
there are no any other indications for the surgery) may 
be a punch biopsy of the spleen under ultrasound moni-
toring that, however, cannot be applied as a routine di-
agnostic method [20].
All patients of our group developed clear therapeutic 
indications for splenectomy: immune cytopenia (AIHA or 
ОНКОЛОГИЯ •  Т.  19 •  № 2 •  2017
ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ
108
AIHA + ITP) which was refractory to previous therapy in 15 
(54%) patients, and massive splenomegaly with abdominal 
signs and portal hypertension (in 6 patients of group 1 and 
in 14 patients of group 2, totally — 71% of patients). Some 
researchers qualify signs of hypersplenism as indications for 
the surgery in patients with NHL [5, 12, 19], which may in-
clude massive splenome galy, thrombocytopenia, leukocy-
topenia, the immune origin of which is difficult to confirm 
in patients with NHL, and portal hypertension.
Splenectomy in case of massive splenomegaly is tech-
nically relatively difficult due to splenic adhesion to oth-
er organs of abdominal cavity and its vascularization [7, 
8, 21]. We did not apply preliminary ligation of the sple-
nic artery trunk, injection of adrenaline into the spleen 
for reducing its size, as it was recommended by some 
researchers. In our opinion, thereby we reduce the risk 
of ischemia of a pancreatic tail segment.
Different perioperative mortality rates in patients with 
NHL undergoing splenectomy are presented in the refe-
rences — from 0% [16], 1% [8], 2.9% [17], 3.5% [18] to 3.8% 
[19], and the postoperative mortality within one month is 
reported in 9% of patients [12]. There were no incidences of 
perioperative mortality in patients of the group represented 
in the study (0%), however, 2 (7%) patients of group 2 died 
of T-cell lymphoma progression and hemorrhagic syndrome 
one month after the surgery. The postoperative complica-
tions (pneumonia, bleeding, thrombosis, pancreatitis) oc-
curred in 5 (18%) patients that coincides with the data re-
ported in the refe rences (17% 37% [17], 29% [5], 21% [12], 
19.2% [19], 17% [16]). The complications after splenectomy 
in patients with NHL can be divided into four types: those re-
sulting from the disease severity; complications arising from 
technical difficulties during the surgery; suppurative septic 
and thrombotic complications.
The immediate clinical hematologic effect after the sur-
gery achieved in 93% of patients: 100% in patients with NHL 
associated with AIHA and 89% in those with NHL associ-
ated with AIHA + ITP. The investigators confirm the high 
response rate to splenectomy in patients with NHL: 89% [5], 
80% [16], 72% [17], 64% in patients with NHL associated 
with AIHA and 89% in patients with NHL associated with 
ITP [12] and report that 90–100% of patients became in-
dependent of red blood cell and platelet transfusions after 
the surgery [8].
The overall survival rate of patients with NHL after sple-
nectomy was slightly better in patients of group 2, and the 
event-free survival rate — in patients of group 1, notwith-
standing that the survival curves did not differ in both groups. 
The similar survival rates of the patients with NHL after sple-
nectomy are reported by other researchers [5, 8, 12, 17]. The 
obtained results prove the statement of some investigators 
that operative treatment success depends mainly on NHL 
variant rather than pre sence or absence of concomitant cy-
topenia [8]. Among patients participating in the study, the 
shortest survi val time after splenectomy was in those with 
aggressive lymphomas associated with immune cytopeni-
as (DLBCL, T-cell). The simultaneous anemia, thrombo-
cytopenia and leucopenia are the adverse prognostic signs 
of the splenectomy efficacy in patients with NHL associat-
ed with AIHA and ITP: 5 such patients of group 2 died 1 to 
12 months after the surgery. Some researchers found the 
considerable survival time in patients with SMZL/SLVL [13, 
14], how ever, in our group of patients it constituted on av-
erage only 39.8 months, only one patient with SMZL re-
mained alive for 143 months after splen ectomy. The partic-
ular splenic subtype of MCL with continuous remission af-
ter splen ectomy is described in the references [19, 22]. We 
now follow one patient with MCL who had leukemic bone 
marrow and blood patterns and underwent lifesaving sple-
nectomy due to massive splenome galy, AIHA, and throm-
bocytopenia. He has been living without signs of lympho-
ma and therapy for 290 months after the surgery.
In case of massive splenomegaly, the spleen represents 
a great tumor mass. Five patients with a giant spleen un-
derwent chemotherapy before the surgery without con-
siderable effect: splenic size did not reduce, hemolysis 
and thrombocytopenia were preserved. Only one patient 
of group 1 and six patients of group 2 (25%) needed cy-
tostatic therapy after splenectomy. The removal of a sub-
stantial tumor mass with spleen leads to improvement of 
the NHL course and response to treatment.
Those who had underwent splenectomy have 2 to 3 times 
higher risk of infection development (pneumonia, meningi-
tis, sepsis), 2 times higher risk of deep vein thrombosis, in-
cluding, 4.5 higher risk of pulmonary embolism [9] and por-
tal venous thrombosis [8, 23]. We ascertain one (4%) case 
of post-splenectomy infection with fatal outcome in patient 
with SMZL + AIHA 9 months after the surgery. Smeltzer et 
al. [8] while examining 60 patients who had undergone sple-
nectomy due to hematological pathology found the asymp-
tomatic portal and splenic vein thrombosis in 38.3% of pa-
tients, whereby, in 5% of cases it  as led to death.
Thus, despite considerable achievements in the field 
of modern hematology and surgery in treatment of NHL 
associated with immune cytopenias, splenectomy re-
mains a serious challenge for specialists and requires 
a thorough approach in every clinical case.
CONCLUSIONS
1. Splenectomy remains an effective and relatively safe 
diagnostic and therapeutic method for treating NHL asso-
ciated with immune cytopenias, particularly, in the presence 
of massive splenomegaly, hypersple nism and RPH.
2. Splenectomy in case of massive splenomegaly is 
technically relatively difficult depending on splenic size, 
adhesion to other organs of abdominal cavity and its vas-
cularization. The perioperative mortality may be avoid-
ed under condition of proper pre- and intraoperative pa-
tient care, and the postoperative mortality rate (lympho-
ma progression, bleeding) equals to 7%.
3. As a result of splenectomy, the final diagnosis of 
NHL variant was specified or determined in 43% of pa-
tients, hemolysis relieved, hemoglobin and thrombo-
cytes level stabilized, abdominal discomfort was elim-
inated, and the need for chemotherapy was reduced in 
93% of patients.
4. The long-term outcomes of splenectomy and surviv-
al of patients with NHL depend mostly on NHL variant 
rather than presence or absence of concomitant cytopenia.
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ЕФЕКТИВНІСТЬ СПЛЕНЕКТОМІЇ 
ПРИ НЕхОДЖКІНСЬКИх ЛІМФОМАх, 
УСКЛАДНЕНИх АУТОІМУННОЮ 
ГЕМОЛІТИЧНОЮ АНЕМІЄЮ 
ТА СИНДРОМОМ ЕВАНСА — ФІШЕРА
Ю.Л. Євстахевич, Я.І. Виговська, І.Й. Євстахевич, 
М.М. Семерак, Г.Б. Лебедь, В.Є. Логінський
Резюме. Мета: визначити показання, хірургічну 
техніку і наслідки спленектомії при неходжкінських 
лімфомах (НХЛ), ускладнених аутоімунною гемо­
літичною анемією (АІГА) або синдромом Еванса — 
Фішера (СЕФ), на основі двадцятирічного досвіду ви­
конання таких операцій. Об’єкт і методи: проведено 
10 спленектомій при НХЛ, ускладненій АІГА (I гру­
па), та 18 спленектомій — при НХЛ, ускладненій 
АІГА та імунною тромбоцитопенією — СЕФ (II гру­
па). Результати оцінювали безпосередньо після опе­
рації та при тривалому спостереженні протягом 
3–201 міс (медіана 68 міс) у І групі та 1–290 міс (ме­
діана 195,5 міс) — у ІІ групі. Результати: показання 
до спленектомії при НХЛ — наявність імунних цито­
пеній, резистентних до кортикостероїдів і цитоста­
тичної терапії, які супроводжуються масивною спле­
номегалією, регіонарною портальною гіпертензією та 
гіперспленізмом. Операція спленектомії при масивній 
селезінці технічно досить складна, залежить від роз­
міру органа та наявності прилягання. Післяоперацій­
на смертність (прогресування лімфоми, кровотеча) 
становить 7%. У 93% хворих спостерігали позитив­
ний безпосередній результат хірургічного втручання. 
При НХЛ, ускладненій АІГА, медіана безподійної вижи­
ваності після операції становила 29 міс (12–49 міс), 
а загальної виживаності — 31,0 міс (18,1–52,2 міс) 
з 3­річною виживаністю 45% пацієнтів і 5­річною — 
22%. У хворих на НХЛ із СЕФ медіана безподійної ви­
живаності сягала 22 міс (5–52 міс), а медіана загальної 
виживаності — 50 міс (12–97 міс), причому 3­річну ви­
живаність відмічено у 62% хворих, а 5­річну — у 31%. 
Найменша тривалість життя після спленектомії за­
фіксована у хворих на агресивні лімфоми, ускладнені 
імунними цитопеніями (B­великоклітинна дифузна 
лімфома, T­клітинні лімфоми). Висновки: спленекто­
мія залишається ефективним і доволі безпечним діа­
гностично­лікувальним методом при НХЛ, ускладне­
них імунними цитопеніями, особливо за наявності ма­
сивної спленомегалії, регіонарної портальної гіпертензії 
та гіперспленізму. Віддалені результати спленектомії 
значною мірою залежать від варіанта НХЛ.
Ключові слова: неходжкінська лімфома, 
спленектомія, аутоімунна гемолітична анемія, 
імунна тромбоцитопенія.
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